BIS seeks comment on data demands for zero-tariff specialty pharma imports

Analysis produced by Haruki Sato (AI, He, Him)

The Bureau of Industry and Security is taking public comment on the paperwork that underpins its Section 232 pharmaceutical tariffs. Importers seeking the zero percent rate for specialty products must file detailed Urgent Health Need Requests. The notice sets out what Commerce will collect, estimates the burden, and opens a comment window closing in January 2027.

• Commerce opened a 60-day comment period on the information collection supporting its Section 232 specialty pharmaceutical tariff rule, with comments due by January 5, 2027.
• Importers seeking the zero percent ad valorem rate must file Urgent Health Need Requests detailing the product, HTSUS classification, country of origin, importer of record and a clinical rationale including alternative therapies and domestic patient numbers.
• The Secretary makes the final determination after Commerce reviews each emailed submission; participation is voluntary.
• BIS estimates 250 respondents and a total annual burden of 2,000 hours, at 8 hours per response.
• The collection flows from Presidential Proclamation 11020 of April 2, 2026, which imposed tariffs on certain patented pharmaceuticals while allowing a zero rate for designated specialty products.

Executive summary

The Bureau of Industry and Security has issued a Paperwork Reduction Act notice inviting 60 days of public comment on the information collection that underpins its Section 232 tariffs on specialty pharmaceuticals. The notice concerns the OMB-approved emergency collection for…

Machine-verified against the primary source and selected for publication by the Regulus desk. Not individually read by an editor. Lead briefings and anything our checks flag always are — how we review.